Document is current
Any future updates will be listed below
-
Authors
Huuhtanen, Jani https://orcid.org/0000-0003-2750-4033
Chen, Liang
Jokinen, Emmi
Kasanen, Henna
Lönnberg, Tapio https://orcid.org/0000-0003-4484-5657
Kreutzman, Anna
Peltola, Katriina
Hernberg, Micaela
Wang, Chunlin
Yee, Cassian https://orcid.org/0000-0002-4429-7307
Lähdesmäki, Harri
Davis, Mark M. https://orcid.org/0000-0001-6868-657X
Mustjoki, Satu https://orcid.org/0000-0002-0816-8241
- License Information
-
More Information
Article History
Received: 28 June 2022
Accepted: 15 September 2022
First Online: 11 October 2022
Competing interests
: M.H. has received honoraria from Pierre Fabre, Novartis, Bristol-Myers Squibb (B.M.S.), Merck Sharp & Dohme (M.S.D.), Roche, Amgen, Sanofi, and Incyte. S.M. has received honoraria and research funding from B.M.S. and research funding from Novartis and Pfizer. M.M.D. has received honoraria and/or equity from Amgen, Chugai, Vir, IGMS, Janux, A2, 3T, Mozart, Red Tree, and research funding from Sanofi. The remaining authors declare no competing interests.
